C099 | IMPROVED METABOLIC PROFILE IN PACRITINIB-TREATED PATIENTS WITH MYELOFIBROSIS: A POOLED ANALYSIS OF PROSPECTIVE CLINICAL TRIALS
Background: Serum albumin is a prognostic marker in patients with myelofibrosis (MF), with levels <4.3 g/dL associated with inferior survival [Tefferi A, et al. Blood Adv. 2018]. Retrospective data suggest that ruxolitinib is associated with increases in albumin [Kuykendall AT, et al. JCO Precision...
Gorde:
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Ferrata Storti Foundation
2025-09-01
|
| Saila: | Haematologica |
| Sarrera elektronikoa: | https://haematologica.org/article/view/12763 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|